Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) to a strong-buy rating in a research note released on Tuesday morning,Zacks.com reports.

Separately, JPMorgan Chase & Co. started coverage on shares of Zealand Pharma A/S in a research note on Friday, November 8th. They set an “overweight” rating on the stock.

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF traded up $2.12 during trading hours on Tuesday, reaching $102.98. The company had a trading volume of 259 shares, compared to its average volume of 901. The firm has a market cap of $7.31 billion, a PE ratio of -42.38 and a beta of 0.89. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The business’s 50 day moving average price is $102.26 and its 200-day moving average price is $117.80. Zealand Pharma A/S has a 1-year low of $65.26 and a 1-year high of $141.74.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.